Graves Ophthalmopathy: all 198 studies
Page 1 of 2. Open to participants first (60), then studies with results posted, then the rest; newest registration first within each.
- Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye DiseaseRecruitingNCT07885605Phase 1
- Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)Not yet recruitingNCT07883356Phase 2
- Transconjunctival Versus Transcutaneous Betamethasone for Upper Eyelid Retraction in TEDNot yet recruitingNCT07866261Not applicable
- Comparative Evaluation of 68Ga-FAPI and 68Ga-DOTATATE PET/CT and PET/MRI in Thyroid Eye DiseaseRecruitingNCT07835607
- An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to TeprotumumabNot yet recruitingNCT07832136Phase 4
- Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' DiseaseNot yet recruitingNCT07812194
- Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye DiseaseNot yet recruitingNCT07762105Phase 1
- Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)RecruitingNCT07753603Phase 3
- A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye DiseaseNot yet recruitingNCT07720648Phase 3
- A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye DiseaseNot yet recruitingNCT07720635Phase 3
- Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE National Multicenter Registry StudyRecruitingNCT07716397
- Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE)Not yet recruitingNCT07623993
- Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM)Not yet recruitingNCT07623837
- A Study of IBI3031 in Participants With Thyroid Eye DiseaseRecruitingNCT07622368Phase 1
- Treatment of Chronic Thyroid Eye Disease With MHB018ARecruitingNCT07622121Phase 3
- Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled StudyRecruitingNCT07622108Phase 3
- Open-Label Extension Study of MHB018A in Patients With Thyroid Eye DiseaseNot yet recruitingNCT07620405Phase 3
- A Clinical Study of Cizutamig in Thyroid Eye DiseaseRecruitingNCT07597200Phase 1
- Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic NeuropathyNot yet recruitingNCT07594912Phase 2
- Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye DiseaseRecruitingNCT07547930Phase 2
- Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves DiseaseRecruitingNCT07480720
- An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)Not yet recruitingNCT07462130Phase 1/2
- An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye DiseaseRecruitingNCT07438405Phase 2
- Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.RecruitingNCT07423013Not applicable
- A Study of VV-14305 for the Treatment of Thyroid Eye DiseaseRecruitingNCT07404111Phase 1/2
- Statin and Vitamin D Treatment in Patients With Thyroid Eye DiseaseRecruitingNCT07400757Not applicable
- Eye Tracking Study on Eye Movement Function and Visual Attention Patterns in Patients With Thyroid-Associated OphthalmopathyRecruitingNCT07381413
- Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients With Graves DiseaseEnrolling by invitationNCT07332988Not applicable
- Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye DiseaseNot yet recruitingNCT07308964Phase 4
- A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye DiseaseRecruitingNCT07265258Phase 4
- Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye DiseaseRecruitingNCT07262476Phase 3
- Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAORecruitingNCT07152392Phase 4
- Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.RecruitingNCT07152366Phase 4
- The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.RecruitingNCT07152340Phase 4
- Construction and Application of Precise Diagnosis and Treatment System for Thyroid-associated OphthalmopathyRecruitingNCT07124572
- A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye DiseaseRecruitingNCT07113262Phase 3
- A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated OphthalmopathyRecruitingNCT06927375Phase 4
- A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.Not yet recruitingNCT06769984Phase 1/2
- Multi-center Prospective Clinical Study on Glucocorticoid Pulse Therapy for Graves' Ophthalmopathy (GO)Enrolling by invitationNCT06693856Not applicable
- Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated OphthalmopathyRecruitingNCT06590220
- Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's OphthalmopathyRecruitingNCT06588764Not applicable
- A Study of GenSci098 in Subjects With Active Thyroid Eye DiseaseRecruitingNCT06569758Phase 1
- A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves OrbitopathyNot yet recruitingNCT06510114Phase 4
- Study on Efficacy of Add on Selenium in Mild-to-moderate Graves OphthalmopathyNot yet recruitingNCT06413043Not applicable
- Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)RecruitingNCT06392906Phase 3
- Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye DiseaseRecruitingNCT06359795Not applicable
- The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid DysfunctionRecruitingNCT06275373
- Evaluation of the Corneal Endothelial Cell Layer by Specular Microscopy in Patients With Thyroid Eye DiseaseNot yet recruitingNCT06235372
- Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)RecruitingNCT06112340Phase 2/3
- Hydroxychloroquine in Mild Graves' OrbitopathyRecruitingNCT05126147Phase 4
- Multi-model Image of Doxycycline in TAORecruitingNCT05112211Not applicable
- Multi-model Image of Immunosuppressive Agents in TAORecruitingNCT05110040Not applicable
- A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 StudyNot yet recruitingNCT05049603Phase 3
- Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic SettingRecruitingNCT05012033
- Sirolimus vs Corticosteroids in Treatment of Thyroid Eye DiseaseRecruitingNCT04936854Phase 2
- A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' OrbitopathyRecruitingNCT04776993Phase 3
- Sirolimus for Graves' Orbitopathy (GO)Not yet recruitingNCT04598815Phase 2
- Bimatoprost as a Treatment for Graves' OrbitopathyRecruitingNCT03708627Early Phase 1
- Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)RecruitingNCT03131726Phase 3
- A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' OrbitopathyNot yet recruitingNCT03098225Phase 4
- A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)CompletedNCT06384547Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye DiseaseCompletedNCT06226545Phase 2Results posted
- An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301CompletedNCT06179875Phase 3Results posted
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye DiseaseCompletedNCT06106828Phase 3Results posted
- An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)CompletedNCT06021054Phase 3Results posted
- Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye DiseaseCompletedNCT05987423Phase 3Results posted
- A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)CompletedNCT05276063Phase 2/3Results posted
- A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)CompletedNCT05176639Phase 3Results posted
- A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)TerminatedNCT04737330Phase 3Results posted
- A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye DiseaseCompletedNCT04583735Phase 4Results posted
- Anti-VEGF Therapy for Acute Thyroid Eye DiseaseTerminatedNCT04311606Phase 2Results posted
- ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )TerminatedNCT03938545Phase 2Results posted
- Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)CompletedNCT03922321Phase 2Results posted
- Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension StudyCompletedNCT03461211Phase 3Results posted
- Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical StudyCompletedNCT03298867Phase 3Results posted
- Glucocorticoids and Bone in Graves' OphthalmopathyCompletedNCT03122847Results posted
- Celecoxib for Thyroid Eye DiseaseTerminatedNCT02845336Phase 2Results posted
- Rituximab (RTX) Therapy in Patients With Active TAOCompletedNCT02378298Phase 4Results posted
- Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye DiseaseCompletedNCT01868997Phase 2Results posted
- Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye DiseaseCompletedNCT01798966Not applicableResults posted
- A Safety and Tolerability Study of Otelixizumab in Thyroid Eye DiseaseTerminatedNCT01114503Phase 2Results posted
- Trial of Rituximab for Graves' OphthalmopathyCompletedNCT00595335Phase 2/3Results posted
- Microbiota and Immune SignatureS of Graves' Disease and OrbitopathyActive, not recruitingNCT07870161Not applicable
- Development of a Non-Invasive Prognostic Test for Graves OrbitopathyActive, not recruitingNCT07472062Not applicable
- Triamcinolone Acetonide Injection for Upper Eyelid Retraction in Thyroid Eye DiseaseCompletedNCT07471997Not applicable
- Psychological Burden of Thyroid Eye DiseaseCompletedNCT07444190
- MHB018A Treatment in Patients With Chronic Thyroid Eye DiseaseActive, not recruitingNCT07257185Phase 3
- A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye DiseaseActive, not recruitingNCT07211776Phase 3
- A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)CompletedNCT07155668Phase 3
- A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese ParticipantsCompletedNCT07142642Phase 1
- Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease PatientsCompletedNCT07085117
- Multi-modal Medical Images for Extraocular Muscle Fibrosis AssessmentCompletedNCT07056114
- MHB018A Treatment in Patients With Active Thyroid Eye DiseaseActive, not recruitingNCT06989918Phase 3
- A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)Active, not recruitingNCT06812325Phase 3
- An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)Active, not recruitingNCT06625411Phase 3
- An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)Active, not recruitingNCT06625398Phase 3
- Establishment of Multimodal-multiparametric Progressive Prediction Models for Thyroid Associated OphthalmopathyCompletedNCT06585592
- A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye DiseaseActive, not recruitingNCT06557850Phase 1
- A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye DiseaseCompletedNCT06525506Phase 2
- Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)TerminatedNCT06467435Phase 1